Are you an innovator or a follower? There is no right or wrong answer. Just know which you are. Otherwise, you are getting in the way. Image via Unsplash

Everyone likes to consider themselves innovators, or at least believe that innovation is happening in their domain. But innovation management is a process that requires leaders to commit deeply and believe that the risk is worth the reward.

For many business leaders, regardless of the industry, it can be a struggle to embrace creativity and innovation and to commit the needed resources of time, funding, and staff to develop new methods of doing business. For many, it is a conflict to invest when there is not a clear, immediate, or guaranteed financial return on investment. When it comes to innovation, the biggest return on investment can be the learnings and the mindset shift, not just the financial gains.

Leaders need to ask themselves a couple of questions:

“Do I want to be an innovator or a follower?” There is no right answer as both leaders and followers are needed. But one thing to keep in mind is that innovation without failure is impossible.

Thus, the next question emerges: “Which do I value more, taking reasonable risks and learning or being a mainstream adopter?” And again, there is no right answer.

Seth Godin, author and former dot com executive, once said, “No organization ever created an innovation. People innovate, not companies.”

With that in mind, for those who genuinely want to be leaders of innovation, there are certain “must-haves” for any process. The most important “must-haves” are remembering that internal culture impacts success and support from the top down is absolutely integral.

Real innovation moves the organization forward strategically. 

Designate ownership and accountability to measure progress. These measurements will often look quite different from other success metrics, are often more opaque and are even not immediately financial. These non-financial metrics sometimes make team members feel uncomfortable, and that is okay. Ultimately everyone involved in this process needs to be willing to hear truth and be committed to creating a culture that drives creativity.

Innovation has a clear alignment with organizational business strategy. 

Leadership and designated team members need defined problems to solve that align with the stated business strategies. There is no point innovating a widget or process that does not move the organization forward.

Innovation requires a defined process and funding. 

Leadership should begin by carving out one full year of budget solely dedicated to innovation and trying new things. These dedicated resources include funding, full-time employees, and support from a consultant, such as EPIcenter, to challenge leaders and drive the process. There must be buy-in by the team members with leaders committed to ongoing sightlines of the process.

The right team members need to be at the table.

The right people need to be the ones to make decisions, evaluate innovations and de-risk both the technology and the business models to make things happen. The team should include individuals who are adaptive and tenured, new and nimble, and a mix of subject matter expertise and enthusiasm.

Innovation success requires the right mindset.

Both the leadership and innovation team must have a mantra of “how can we” rather than “we can’t” or “we’ve never done it that way before” or “it failed before.” There must be a will and desire to work, innovate, fail, resolve, and execute -- or at least learn.

Sometimes innovative solutions emerge by happenstance during the process without a known or stated problem. With proper training and a curious mindset anything is possible.

With these requirements in mind, let’s go back to the initial questions asked of business leaders, but in reverse order this time:

“What do you value more, taking reasonable risks and learning while meeting strategic goals or pure financial gain?”

“Are you okay with failure, adjustments and trying again?”

“Are you an innovator or a follower?”

Again, there is no right or wrong answer. Just know which you are. Otherwise, you are getting in the way.

------

Liz Thompson serves as the chief of advisory services at EPIcenter, a Texas-based nonprofit organization with a think tank, incubator, and accelerator focused on energy innovation and thought for the global future.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.